An oncolytic virus–T cell chimera for cancer immunotherapy

Menée à l'aide de lignées cellulaires, de modèles murins de cancer et d'échantillons sanguins d'origine humaine, cette étude met en évidence l'intérêt thérapeutique de lymphocytes T conjugués à un adénovirus oncolytique qui, en exprimant dans les cellules cancéreuses l'endonucléase CAS9, réduit l'expression de PD-L1

Résumé en anglais

The efficacy of oncolytic adenoviruses (OAs) for cancer therapy has been limited by insufficient delivery to tumors after systemic injection and the propensity of OAs to induce the expression of immune checkpoints. To address these limitations, we use T cells to deliver OAs into tumors and engineer the OA to express a Cas9 system targeting the PDL1 gene encoding the immune checkpoint protein PD-L1. By cloaking OAs with cell membranes presenting T cell-specific antigens, we physically conjugated OAs onto T cell surfaces by antigen–receptor interaction. We tested the oncolytic virus–T cell chimera (ONCOTECH) via intravenous delivery in mouse cancer models, including models of melanoma, pancreatic adenocarcinoma, lung cancer and glioblastoma. In the melanoma model, the in vivo delivery of ONCOTECH resulted in a strong accumulation of OAs in tumor cells, where PD-L1 expression was reduced by 50% and the single administration of ONCOTECH enabled 80% survival over 70 days. Collectively, ONCOTECH represents a promising translational technology to combine virotherapy and cell therapy.